Pharmabiz21h
Dizal seeks US FDA approval for sunvozertinib to treat relapsed or refractory NSCLC with EGFR Exon 20 insertion mutations
Dizal seeks US FDA approval for sunvozertinib to treat relapsed or refractory NSCLC with EGFR Exon 20 insertion mutations: Shanghai, China Saturday, November 9, 2024, 17:00 Hrs [I ...
Pharmabiz20h
SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting
SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting: Stamford, Connecticut Saturday, N ...
Pharmabiz23h
Adaptive Biotechnologies get expanded medicare coverage of clonoSEQ for assessing measurable residual disease in mantle cell lymphoma
Adaptive Biotechnologies get expanded medicare coverage of clonoSEQ for assessing measurable residual disease in mantle cell lymphoma: Seattle Saturday, November 9, 2024, 15:00 Hr ...
Pharmabiz22h
Serres Group receives €1.8 million research grant from Business Finland
Serres Group receives €1.8 million research grant from Business Finland: Espoo, Finland Saturday, November 9, 2024, 16:00 Hrs [IST] Serres has been granted a substantial researc ...
Pharmabiz18h
Transgene & NEC to present new data confirming clinical proof of principle for neoantigen cancer vaccine, TG4050, in head & neck cancer at SITC 2024
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a leader in IT, network and AI technologies, announced 24.1 month ...